 Shareholder rights law firm Robbins LLP announces that it is investigating Immunomedics, Inc. NASDAQ: IMMU for alleged violations of the Securities Exchange Act of 1934 and whether the Companys officers and directors breached their fiduciary duties to shareholders. Immunomedics, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer. The company is developing its antibody-drug conjugate IMMU-12. 